Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

Blood

Volumn 120, Issue 2, 2012, Pages 376-385

  Chesi, Marta ^a   Matthews, Geoffrey M ^b,c   Garbitt, Victoria M ^a   Palmer, Stephen E ^a   Shortt, Jake ^b,c   Lefebure, Marcus ^b,c   Stewart, A Keith ^a   Johnstone, Ricky W ^b,c   Leif Bergsagel, P ^a  

^a MAYO CLINIC   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 5 AZA 2' DEOXYCYTIDINE; ATORVASTATIN; BORTEZOMIB; CARFILZOMIB; CICLOPIROXOLAMINE; CLADRIBINE; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; HEMOGLOBIN; HYDROXYUREA; LENALIDOMIDE; MELPHALAN; MEVINOLIN; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; OBATOCLAX; PACLITAXEL; PANOBINOSTAT; POMALIDOMIDE; PR 047; PURVALANOL; ROMIDEPSIN; TAK 901; UNCLASSIFIED DRUG; VINCRISTINE; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; CANCER MODEL; CANCER STAGING; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FLOW CYTOMETRY; GENETIC ENGINEERING; HISTONE ACETYLATION; HUMAN; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMACYTOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT RESPONSE;

EID: 84864040412     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-412783     Document Type: Article

References (42)

1. Bergsagel DE, Griffith KM, Haut A, Stuckey WJ. The treatment of plasma cell myeloma. Adv Cancer Res. 1967;10:311-359.
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
3. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-715. (Pubitemid 39173511)
4. Francia G, Kerbel RS. Raising the bar for cancer therapy models. Nat Biotechnol. 2010;28(6):561-562.
5. Jackson DV, Case LD, Pope EK, et al. Single agent vincristine by infusion in refractory multiple myeloma. J Clin Oncol. 1985;3(11):1508-1512. (Pubitemid 16246764)
6. Ocana A, Pandiella A, Siu LL, Tannock IF. Pre-clinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol. 2010;8(4): 200-209.
7. Witzig TE, Gonchoroff NJ, Katzmann JA, Therneau TM, Kyle RA, Greipp PR. Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. J Clin Oncol. 1988;6(6):1041-1046.
8. Singh M, Lima A, Molina R, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol. 2010;28(6):585-593.
9. Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008;13(2):167-180. (Pubitemid 351163163)
10. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A. 2000;97(1):228-233. (Pubitemid 30055813)
11. Singbrant S, Russell MR, Jovic T, et al. Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood. 2011;117(21):5631-5642.
12. Spurr AR. A low-viscosity epoxy resin embedding medium for electron microscopy. J Ultrastruct Res. 1969;26(1):31-43.
13. Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood. 2002;100(12):4162-4168. (Pubitemid 35396884)
14. Ocio EM, Vilanova D, Atadja P, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2009;95(5):794-803.
15. Chauhan D, SinghAV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2010; 115(4):834-845.
16. Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity. 2001;15(2): 289-302. (Pubitemid 32816877)
17. Richardson PG, Mitsiades CS, Colson K, et al. Final results of a phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110(11):Abstract 1179.
18. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2004;101(2):540-545. (Pubitemid 38084672)
19. Dimopoulos M-A, Jagannath S, Yoon S-S, et al. Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial. [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 811.
20. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904-917.
21. Hu J, Handisides DR, Van Valckenborgh E, et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood. 2010;116(9):1524-1527.
22. Dimopoulos MA, Arbuck S, Huber M, et al. Primary therapy of multiple myeloma with paclitaxel (taxol). Ann Oncol. 1994;5(8):757-759. (Pubitemid 24302694)
23. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745-4753.
24. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892-3901. (Pubitemid 47477266)
25. Blade J, Fernández de Larrea C, Rosiñol L, Cibeira M-T, Jiménez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805-3812.
26. Short KD, Rajkumar SV, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906-908.
27. Sellers WR. A blueprint for advancing genetics-based cancer therapy. Cell. 2011;147(1):26-31.
28. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310(21): 1353-1356. (Pubitemid 14149087)
29. Wolf JL, Siegel D, Matous J, et al. A phase II study of oral panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11):Abstract 2774.
30. Rossi JF, Moreaux J, Hose D, et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study. Br J Cancer. 2009;101(7):1051-1058.
31. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131-144. (Pubitemid 47208626)
32. Thompson MA, Kyle RA, Melton LJ, Plevak MF, Rajkumar SV. Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance: a case-control study. Haematologica. 2004;89(5):626-628. (Pubitemid 38691260)
33. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609- 2617. (Pubitemid 36741588)
34. Vij R, Siegel DS, Kaufman J, et al. Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma [abstract]. J Clin Oncol. 2010; 28(suppl):15s. Abstract 8000.
35. Dimopoulos MA, Kantarjian HM, Estey EH, Alexanian R. 2- Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood. 1992; 80(6):1626.
36. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med. 1986;105(1):8-11. (Pubitemid 16097913)
37. Kraut EH, Crowley JJ, Grever MR, et al. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. Invest New Drugs. 1990;8(2):199-200. (Pubitemid 20184235)
38. Davis P. Phase Ii Studies of hydroxyurea (Nsc-32065) in adults: multiple myeloma and lymphoma. Cancer Chemother Rep. 1964;40:51-52.
39. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002; 100(9):3063-3067. (Pubitemid 35217050)
40. Richardson P, Lonial S, Jakubowiak A, et al. Multi-center phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/ refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110(11):Abstract 1164.
41. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22(16):3269-3276. (Pubitemid 41103682)
42. Niesvizky R, Ely S, Mark T, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011;117(2):336-342.